Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski

Blood (2023) 142 (16): 1348–1358.

https://doi.org/10.1182/blood.2023020637

Published: 2023

Includes: Supplemental data

Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-140314

Published: 2020

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

https://doi.org/10.1182/blood-2019-128388

Published: 2019

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 1582.

https://doi.org/10.1182/blood-2019-122573

Published: 2019

Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MDPhD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Aleš Obr, MD, Gianluca Gaidano, MD PhD, Marc Andre, MDPhD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD

Blood (2018) 132 (Supplement 1): 227.

https://doi.org/10.1182/blood-2018-99-113399

Published: 2018

Journal Articles

Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy

Philipp Bernhard Staber, MD PhD, Asher A. Chanan-Khan, MD, Talha Munir, Dietger Niederweiser, Johannes Schetelig, MD MSc, Jan Moritz Middeke, MD, Maren Dirnberger-Hertweck, PhD, Peter Kelemen, Johannes Weirather, PhD, Sameer A. Parikh, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Jennifer A. Woyach, MD

Blood (2018) 132 (Supplement 1): 4433.

https://doi.org/10.1182/blood-2018-99-114489

Published: 2018

Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, MD PhD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, PhDMD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Tomáš Papajik, MD PhD, Gianluca Gaidano, MD PhD, Marc Andre, MD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Sumeet Ambarkhane, MD, Johannes Weirather, PhD, Maren Dirnberger-Hertweck, PhD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 4123.

https://doi.org/10.1182/blood.V130.Suppl_1.4123.4123

Published: 2017

Journal Articles

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Gianluca Gaidano, MD PhD, Andre Goy, MD, Mariano Provencio, MD PhD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD PhD, Kami J. Maddocks, MD, Christian Buske, Sumeet Ambarkhane, MD, Mark Winderlich, PhD, Maren Dirnberger-Hertweck, PhD, Jan Endell, PhD, Kristie A Blum, MD

Blood (2016) 128 (22): 623.

https://doi.org/10.1182/blood.V128.22.623.623

Published: 2016

NARROW

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only